Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy

Cancer

Volumn 82, Issue 10, 1998, Pages 1887-1896

  D'Amico, Anthony V ^a   Desjardin, April ^b   Chung, Arnold ^a   Chen, Ming Hui ^b   Schultz, Delray ^c   Whittington, Richard ^d   Malkowicz, S Bruce ^d   Wein, Alan ^d   Tomaszewski, John E ^d   Renshaw, Andrew A ^e   Loughlin, Kevin ^e   Richie, Jerome P ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Worcester Polytechnic Institute   (United States)

^c University of Millersville   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer volume; Outcome prediction; Prostate carcinoma; Prostate specific antigen; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; DATABASES, FACTUAL; EVALUATION STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 0032525282     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980515)82:10<1887::AID-CNCR11>3.0.CO;2-P     Document Type: Article

References (32)

1. Smith D, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994;152:1732-5.
2. Culp OS. Radical perineal prostatectomy: its past, present, and possible future. J Urol 1968;98:618-25.
3. Jewett HJ, Eggleston JC, Yawn DH. Radical prostatectomy in the management of carcinoma of the prostate: probable causes of some therapeutic failures. J Urol 1972;107:1034-40.
4. Benson RC Jr., Tomera KM, Zincke H, et al. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J Urol 1984; 131:1103-7.
5. Blute ML, Nativ O, Zincke H, et al. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 1989; 142:1262-5.
6. Walsh PC, Partin AW, Epstein, JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6.
7. D'Amico AV, Whittington R, Malkowicz SB, et al. PSA failure despite pathologically organ confined and margin negative disease: the basis for an adjuvant therapy trial. J Clin Oncol 1997;15:1465-9.
8. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. J Am Med Assoc 1997;277:1445-51.
9. Zagars GK, Pollack A, Kavadi VS, et al. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
10. Pisansky TM, Kahn MJ, Rasp GM, et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer 1997;79:337-44.
11. D'Amico AV, Whittington R, Malkowicz SB, et al. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997;158:1422-6.
12. Leibel SA, Zelefsky MJ, Kutcher GJ, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994;21:580-97.
13. Movsas B, Hanlon A, Teshima T, et al. Analyzing predictive models following definitive radiotherapy for prostate cancer [Abstract 46]. Proceedings of the 1997 meeting of the American Radium Society.
14. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for staging cancer. 4th edition. American Joint Committee on Cancer. Philadelphia: J. B. Lippincott, 1992.
15. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
16. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-99.
17. D'Amico AV, Chang H, Holoupka E, et al. Calculated prostate cancer volume: the optimal predictor of the actual prostate cancer volume. Urology 1997;49:385-91.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Amer Stat Assoc 1958;53:457-500.
19. Akaike H. Factor analysis and AIC. Psychometrika 1987;52:317-32.
20. Schwartz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
21. Efron R, Tibsherani R. Introduction to the bootstrap. New York: Chapman and Hall, 1993.
22. Lee WR, Hanks GE, Schultheiss TE, et al. Localized prostate cancer treated by external beam radiotherapy alone: serum prostate specific antigen driven outcome analysis. J Clin Oncol 1995;13:464-9.
23. Pisansky TM, Cha SS, Earle JD, et al. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
24. Zietman AL, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
25. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
26. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-8.
27. Lerner SE, Blute ML, Bergstralh EJ, et al. Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-43.
28. Zietman AL, Edelstein RA, Coen JJ, et al. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-33.
29. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.
30. Carter HB, Pearson JL, Metter J, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 1992;267:2215-20.
31. Roach M, Marquez C, Yuo H-S, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1993;28:33-7.
32. D'Amico AV, Propert K. Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 1996;35:273-9.